ng purification challenges for the
Pharmaceutical, Biopharmaceutical and Industrial Biotech markets. The
company offers laboratory purification equipment as well as large-scale
industrial production plants for producing pure products, and a full range
of services including process development, kg to multi-ton scale custom
purification and performance optimization.
To serve its different markets, Novasep Process offers innovative and
reliable solutions based on Novasep Process proprietary technologies :
Novasep batch and continuous chromatography (high and low pressure) and
crystallization, Applexion(r) ion exchange and evaporation, Orelis(r)
membrane processes.
Novasep Synthesis produces complex molecules using proven and
innovative technologies within certified facilities in France, Germany and
the Bahamas. Novasep offers exclusive synthesis services from lab to
commercial scale to cover the special needs of the Pharmaceutical, Cosmetic
and Agrochemical industries. Novasep sells Reagents, Building Blocks and
Generics as well as performs multi-step synthesis for its customers.
To serve its different customers Novasep Synthesis has developed
know-how and innovative technologies using:
Hazardous Chemistry: Azide, Diborane, Diazomethane, Ozonolysis,
Carbonylation,
Asymmetric technologies: Asymmetric Chemistry, Preparative Chromatography,
Synthesis and Purification of Highly Potent Molecules
and multi-step, multi-ton synthesis.
http://www.novasep.com
For further information please contact: Chromatide Limited; Don Wellings, Chief Scientific Officer;
+44-(0)1928-511222; info@chromatide.com;
http://www.chromatide.com
Novasep; Jean-Marc Le Rudulier, Marketing & Communication Director, Tel
: +33-(0)3-83-49-71-46,
SOURCE Groupe Novasep SAS Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related biology technology :1.
Groupe Novasep to Acquire PharmaChem Technologies (Grand Bahama) Ltd2.
Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant3.
Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma4.
CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)5.
FDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)6.
ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating7.
Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting8.
DiObex and Camurus Sign License Agreement for the Development of DIO-901 in FluidCrystal(R) Extended Release Technology9.
New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition10.
Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes11.
National Survey Shows Most Women Are Not Satisfied With Their Progesterone Treatment